创新药ETF领涨 风险偏好边际回升

Group 1: Market Overview - The innovative drug sector has seen positive news leading to significant gains in related ETFs, with multiple innovative drug ETFs rising over 3% on July 1, 2023, and some gaining over 65% year-to-date [2] - Bond ETFs have attracted substantial inflows, with five bond ETFs among the top ten by net inflow, including the E Fund Corporate Bond ETF, which saw a net inflow of 1.982 billion [3] - The overall market is expected to continue its moderate recovery in July, supported by domestic economic stability and ongoing policy implementation [1] Group 2: Policy Impact on Innovative Drugs - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on R&D, access, hospital use, and multi-payment systems [2] - The measures are seen as a concrete implementation of the State Council's policies, reflecting a strong commitment to the innovative drug sector [2] Group 3: Investment Strategies - The market is expected to shift focus towards high-performing companies as the semi-annual earnings reports approach, with core assets like CSI A500, CSI A50, and CSI 300 being highlighted as stable investment opportunities [4][5] - The innovative drug sector is viewed as a promising investment area due to favorable domestic policies and the potential for increased overseas licensing, with 2025 anticipated to be a significant year for licensing [5]